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We read with interest the paper of Parthasarathy et al. [1],
investigating the blood pressure (BP) response to two
different diuretics [a mineralocorticoid receptor antagon-
ist (MRA) and a thiazide diuretic] in patients subdivided,
according to aldosterone-to-renin ratio (ARR) value, in
high and low ARR group, respectively. Given the high
incidence of primary aldosteronism and the widely recog-
nized adverse effects of aldosterone on cardiovascular
system, further research on MRA use in hypertensive
patients is warranted.
Parthasarathy and colleagues found that spironolactone is
equally effective in the two groups of patients and,
importantly, it is highly powerful (with a mean global
reduction of about 15 mmHg in mean 24-h systolic ambu-
latory BP after 12 weeks of treatment).
However, we would like to have some additional infor-
mation, which was not included in the text, about the sex-
related response to spironolactone. In our study published
in 2008 [2] on primary-care hypertensive patients treated
with potassium kanrenoate (the active metabolite of
spironolactone), we reported that the drug was two-fold
moreeffectiveinreducingSBPinwomenthaninmen(after
2 months of treatment 16.4 versus 8.2 mmHg). More-
over, a subanalysis of the results showed that the larger
effectwasobtainedinpostmenopausalwomensuggestinga
roleofaldosteroneinthisparticularformofhypertension.In
contrast and consistently with Parthasarathy et al.’s data,
patientspreviouslyidentifiedbyaraisedARRdidnothavea
response to MRA treatment statistically different from
patients with normal ratio. Even taking into account the
differences in the study design (intervention study with a
single drug, analyzing office BP measurements versus a
randomized, cross-over trial, analyzing ambulatory BP
monitoring), it should be interesting to verify this aspect
in Parthasarathy et al.’s patients both for the mean 24-h
systolic ambulatory BP and for office SBP.
A confirmation of our previous data could be important
not only for practical purposes but also for the possible
pathogenetic implications that could be drawn.
Finally, we underline that in both studies MRA treat-
ment was very effective and well tolerated, suggestingopyright © Lippincott Williams & Wilkins. Unauth
0263-6352  2010 Wolters Kluwer Health | Lippincott Williams & Wilkinsthe opportunity to reconsider the role of this type of drugs
in hypertension management.
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The clear benefit of treatment in hypertensive indivi-
duals above 80 years of age on nonfatal outcomes, in
particular stroke and heart failure, contrasts with the
remaining uncertainties regarding the fact that treatment
may increase total mortality. The suspicion of deleterious
treatment effects evolved as the evidence accumulated
over time: it was first estimated as a marginally significant
increase of 14% of total mortality in a 1999 systematic
review of limited subgroups from randomized controlled
trials done in larger populations [1] [P¼ 0.05; 95% con-
fidence interval (CI) 0–31; no significant heterogeneity].
In 2003, the results from the Hypertension in the Very
Elderly Trial (HYVET) pilot trial [2], reinforced that
suspicion, with a relative increase in risk of 23% in total
mortality (both results combined: P¼ 0.03; 95% CI 1–31;
no significant heterogeneity). Recently, the HYVET trial
[3] offered the unexpected and apparently reassuring
result: a statistically significant reduction in both
stroke and total mortality was observed at the second
interim analysis after 2 years of follow-up, which led
the investigators to prematurely interrupt the trial.orized reproduction of this article is prohibited.
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follow-up modified somewhat the results of this interim
analysis: the primary outcome, stroke, displayed a risk
reduction of 30% (95% CI1 to 51; P¼ 0.06), and the risk
reduction of death from any cause was a 21% reduction
(95% CI 4–35; P¼ 0.02); unfortunately, these results
were no longer significant when measured against the
a-priori decided [4] threshold of P less than 0.01 for
statistical significance. The most likely interpretation for
this quick evolution of results between the time of decision
and the final completed analysis is that the initial results
were an overestimation of reality, as has been proven to be
the case with early truncation of trials [5]. Whatever the
interpretation of this result, it dramatically weakens the
level of evidence of HYVET, which has to be considered as
an inconclusive trial, when considered alone.
As expected from the pooling of two results, both stat-
istically significant but in opposite directions, the
updated meta-analysis was significantly heterogeneous,
both in terms of statistical significance and clinical
relevance. The probability that the difference between
HYVET results and those from previous synthesis of
evidence was due to chance alone was estimated to be
less than 0.003, that is, a rather unusual level for hetero-
geneity tests, known to be underpowered. This discre-
pancy led us to update our 1999 meta-analysis focusing on
total mortality, exploring possible causes through meta-
regression and eventually concluding that a high intensity
of therapy was to be avoided [6]. In their editorial
commentary, Reboldi et al. [7] have provided interesting
points of discussion about our updated systematic review.
They introduced the debate by suggesting that the dis-
appointing scenario of a high prevalence of uncontrolled
hypertension after 80 years of age may be related to the
promotion of negative results. They suggested that the
lack of evidence in this age group may have influenced
physicians, making them reluctant to adequately treat the
oldest old with hypertension. They build their reasoning
on a mix of HYVET results, those from a subgroup meta-
analysis and the recently published update of the Euro-
pean Society of Hypertension (ESH) guidelines [8],
stating that ‘even in the very elderly stratum of the
population, antihypertensive treatment does not only
prevent cardiovascular morbid events but also translates
into prolongation of life’, and that ‘an evidence-based
general recommendation can now be given to prescribe
antihypertensive treatment to octogenarians with SBP
above 160 mmHg with the target to lower it below
150 mmHg’. First, we do not share their feeling of know-
ing a priori what adequate treatment is, before critically
appraising the results from the best evidence. Second,
their statement that blood pressure (BP) in the oldest old
is not adequately controlled is based on a BP target
defined as SBP less than 140 and DBP less than
90 mmHg, in contradiction with the targets they promote
later on in their commentary. In such discussions, hyper-opyright © Lippincott Williams & Wilkins. Unauthotension definition has to be clearly distinguished from BP
target under treatment, even if both have always been
arbitrary. In addition, differences of 10 or 20 mmHg can
make huge differences in terms of hypertension preva-
lence, or deleterious consequences of treatment. We
think it important to emphasize a particular aspect of
the HYVET protocol: the rules for treatment escalation
were based on a conservative BP target of 150 mmHg, and
no additional treatment was mandated after two drugs in
modest dosage was attained, explaining why 50% of
randomized patients did not achieve the target. Third,
Reboldi et al. [7] did not acknowledge two clear limita-
tions of their rationale: they used the results from
HYVET, which are not statistically significant (see
above) and cited a subgroup meta-analysis concerned
with a population of hypertensive individuals above
65 years of age, which is not relevant for addressing
questions for patients 80 years of age or above.
Then, Reboldi et al. [7] focused their discussion on two
methodological issues, putting into question the reality of
the heterogeneity regarding mortality results on one hand
and possible explanations through meta-regression for
the heterogeneity of mortality results on the other hand.
They correctly stated that the analyzed trials were not
powerful enough to demonstrate a small significant effect
on mortality. In order to illustrate their statement,
Reboldi et al. computed the size of a trial to be powerful
enough to demonstrate a statistically significant 6%
increase of mortality (that observed in our meta-analysis).
This computation is questionable. First, they used an
unusual 0.01 threshold for statistical significance of bilat-
eral test, as did the authors of the HYVET trial, without
justifying it. Second, they based their computation on the
6% increase corresponding to the average point estimate
of a meta-analysis with significant heterogeneity. The
basic principle to deal with a significant heterogeneity
in meta-analysis is to avoid direct interpretation and
a fortiori any prediction based on this point estimate.
If alternatively, we had to compute the sample size for a
trial aiming at testing the hypothesis that overtreatment
would result in a mortality increase, we would use the
point estimate of a meta-analysis that did not display
heterogeneity, that is, that from trials available before the
results of HYVET were published, with usual statistical
significant threshold. We then would have to decide
between the point estimate observed at 3 years, that
is, 35% increase, or that observed after 5 years, that is,
17% increase. The resulting sample size would be suit-
able for a future clinical trial.
The weakness of the available evidence regarding the
impact of antihypertensive treatment on mortality in the
very old comes mainly from the fact that no trial adopted
mortality as the primary outcome. Importantly, we have
to accept that the most powerful clinical trial available to
date is inconclusive. Dealing with this uncomfortablerized reproduction of this article is prohibited.
CCorrespondence 173situation, we must try to explain the heterogeneity and to
inform patients as clearly and honestly as possible using
the best available evidence.
Reboldi et al. [7] stated that we should have used random
effect model to perform the meta-regression, because
‘fixed-effect meta-regression is likely to produce mislead-
ing results in the presence of heterogeneity’. We agree
with their statement and take the liberty to present the
results using their suggestion: the results of the meta-
regression using a random effect model remain significant
and, thus, our conclusions do not change. Most of all, we
observe that their reasoning contradicts their former
claim that the heterogeneity is attributable to unreliable
underpowered data.
The conclusion of our meta-analysis, that a high intensity
of therapy is to be avoided, is based on secondary post-
hoc analyses. However, it is in line with the trend
observed in the meta-regression of observed BP under
treatment, and most of all, it is also in agreement with the
common sense approach of being cautious not to lower
the BP too much in a frail elderly population.
References
1 Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, et al.
Antihypertensive drugs in very old people: a subgroup meta-analysis of
randomised controlled trials. INDANA Group. Lancet 1999; 353:793–796.
2 Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C,
et al. Hypertension in the Very Elderly Trial Working Group. Results of the
pilot trial for the Hypertension in the Very Elderly Trial. J Hypertens 2003;
21:2409–2417.
3 Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al.
Treatment of hypertension in patients 80 years of age or older. N Engl J Med
2008; 358:1887–1898.
4 Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F, et al.
Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial.
Drugs Aging 2001; 18:151–164.
5 Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G. Early stopping of
randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol
2008; 61:241–246.
6 Bejan-Angoulvant T, Saadatian-Elahi M, Wright J, Schron E, Lindholm LH,
Fagard R, et al. Treatment of hypertension in patients 80 years and older: the
lower the better? A meta-analysis of randomized controlled trials.
J Hypertension 2010; 28:1366–1372.
7 Reboldi G, Gentile G, Angeli F, Verdecchia P. Blood pressure lowering in the
oldest old. J Hypertens 2010; 28:1373–1376.
8 Mancia G, Laurent SP, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield
MJ, et al. Reappraisal of European guidelines on hypertension management:




Gianpaolo Reboldia, Giorgio Gentilea, Fabio Angelib and
Paolo Verdecchiac
aDepartment of Internal Medicine, University of Perugia, bDepartment of
Cardiology, Hospital ‘S. Maria della Misericordia’, Perugia and cDepartment of
Medicine, Assisi Hospital, Assisi, Italy
Correspondence to Gianpaolo Reboldi, MD, PhD, MSc, Department of Internal
Medicine, University of Perugia, Italy
E-mail: paolo@unipg.itopyright © Lippincott Williams & Wilkins. UnauthWe thank the authors for their interest in our Commen-
tary [1] and the issues they raised. Our aim in comment-
ing the updated meta-analysis was to promote the
discussion in an area in which important clinical decisions
are frequently made in the absence of conclusive evi-
dence.
It is beyond question that Gueyffier et al. in their letter
highlighted important issues concerning the treatment of
hypertension in the very elderly. However, it seems that
they have somewhat misinterpreted our position and we
apologize if our reasoning was not clear. Our position in
this area is in line with the aphorism of Sir Francis Bacon,
‘If a man will begin with certainties, he shall end in
doubts; but if he will be content to begin with doubts he
shall end in certainties’ [2]. We do not know, and hence
actually we never stated, either ‘a priori’ or ‘a posteriori’,
what ‘adequate treatment’ is for octogenarians. Being far
from certainty, we openly stated that ‘the optimal goals of
antihypertensive therapy in the oldest old have always
been the object of debate’ [1]. Thus, in commenting the
data reported by Bejan-Angoulvant et al. [3], we tried to
delineate the scenario, through a chronologic reconstruc-
tion of available evidence from observational studies,
intervention trials, systematic reviews, and clinical prac-
tice guidelines. Our aim was threefold: define what we
know, what we do not know yet, and highlight the ‘grey
areas’ of uncertainty. We believe that our chronologic
reconstruction of available evidence emphasizes the
limits of current knowledge rather than formally endors-
ing whatsoever position.
We agree with Gueyffier et al. that, as a general rule,
differences of 10 or 20 mmHg can make huge differences
in terms of hypertension prevalence, even if data from
Framingham [4] underscore that more than 60% of indi-
viduals aged 80 or older had blood pressure (BP) values at
least 160/100 mmHg or were receiving treatment. How-
ever, it is also evident that previous studies, cited at the
beginning of our commentary [1], used BP targets
reported in previous guidelines [5,6], whereas only the
recently updated European Society of Hypertension
(ESH) guidelines [7] highlighted the issue of specific
targets in the oldest old. Secondly, we never endorsed the
BP target of 140/90 mmHg. The 140/90 mmHg target was
cited using quotation marks, so there is no contradiction
with the target later reported in our commentary. We
interpret the systolic blood pressure (SBP) target of
150 mmHg, recommended by the updated ESH guide-
lines and not arbitrarily promoted by us, as a cautionary
step which may represents a wise approach at the present
time, until further substantial evidence will become
available. Moreover, the true point of concern is that,
as Hajjar et al. [8] reported 35% of physicians consider
that the increase in BP with age is a normal process
of aging, and 25% consider treating hypertension in an
85-year-old patient to have more risks than benefits.
Therefore, it may appear pointless, if not purelyorized reproduction of this article is prohibited.
C174 Journal of Hypertension 2011, Vol 29 No 1academic, to discuss about the different thresholds for the
diagnosis and the treatment of hypertension in the oldest
old, when a large number of physicians are reluctant to
treat an 80-year-old man. It may be more important to
adequately acknowledge that elderly people may actually
benefit from antihypertensive treatment.
Methodological aspects
Contrary to the perspective of Gueyffier et al., we did not
‘compute the size of a trial to be powerful enough to
demonstrate a statistically significant 6% increase of
mortality’. We concur with them that a realistic interpret-
ation of predictions from a random-effects model can
indeed be difficult in the presence of heterogeneity, but
our concern was the conclusiveness of their meta-analysis
and the potential implication of their relevant findings,
not the predicted effect treatment in a future study.
Consequently, we calculated the optimum information
size (OIS) [9] for this meta-analysis and not the sample
size requirement for a future trial. This unfortunate
misunderstanding makes a huge difference. OIS is the
minimum amount of information required in the collec-
tive literature for reliable conclusions about an interven-
tion to be reached before conducting a new study, that is
whether the results of a series of trials are so extremely
clear that further studies are not needed. With this in
mind, one may wish to set the type I error rate (alpha
level) at least at 0.01 (instead of the commonly used 0.05)
and set power at 90 or 95% [10].
Optimum information size provides a first approximation
of the minimum sample size required, and our illustrative
calculations (assuming a clinically relevant 6% relative
risk increase and a 14% incidence in controls) showed
that using a moderately conservative alpha of 0.01 and
lower-than-recommended power (80%) the required
information size should be at least 159 694. Increasing
power to 90 or 95% (as recommended) would further
increase OIS to 203 272 or 243 232, respectively, whereas
the meta-analysis included only 6701 patients. On this
ground, we concluded that the evidence cumulated so far
was unlikely to be conclusive. Even excluding HYVET
results from the meta-analysis, OIS calculation with alpha
0.01 and power 80, 90 or 95% (assuming a 17% relative
risk increase at 5 years and a 17% mortality in controls, i.e.
the ratios and rates observed excluding HYVET data)
would yield a minimum required information size OIS of
8550, 10 854 and 12 966, respectively, still well above the
2856 patients studied before HYVET. As noted,
inclusion of HYVET introduces a statistically significant
heterogeneity and OIS calculation does not take this into
account explicitly [10]. Heterogeneity indeed affects the
information size and, as recently demonstrated by Wet-
terslev et al. [11] the required information size in a
random-effects model is a monotone increasing function
of the degree of heterogeneity. These authors derived an
adjusting factor for the required information size underopyright © Lippincott Williams & Wilkins. Unauthorandom-effects model meta-analysis using the inconsis-
tency (I2) statistic. To preserve a and b, the correction
factor increases the information size according to the
impact that heterogeneity has on the meta-analysis.
Accordingly, our illustrative estimate (n¼ 159 694), for
an ‘unadjusted’ information size requirements (assuming
near-null inconsistency) would rise to 275 334 when
adjusted using the heterogeneity correction factor based
on 42% inconsistency statistic (i.e. the I2 statistic for this
meta-analysis) [3,11]. Even with a less conservative alpha
set to 0.05 and 80% power, the heterogeneity-adjusted
information size for this meta-analysis would be 95 489,
still well above 6701. Given these figures, we reluctantly
have to accept that this meta-analysis is not conclusive. In
dealing with this uncomfortable situation, we must, how-
ever, carefully balance between significant benefits and
possible, yet unproven, harms.
Gueyffier et al. substantially accepted our suggestion and
came to a conclusion that we already presented in our
commentary: ‘we obtained the same point-estimate (22%
increase) but with much wider 95% confidence intervals
(CIs), spanning from 2 to 45%, and a lower level of
statistical significance (P¼ 0.033 vs. <0.001)’ [1]. Rather
than questioning the level of statistical significance
achieved, our suggestion had to be interpreted as a word
of caution before drawing conclusions about causal
relationships, because a fixed-effects model might be
overoptimistic [12]. Apart from this, the relationship
described by a meta-regression is an observational associ-
ation across trials, and even though the original studies
are randomized trials, the meta-regression is across trials
and does not have the benefit of randomization to under-
pin a causal interpretation [12].
As correctly stated by Gueyffier et al. the conclusion of
this meta-analysis, that a high intensity of therapy is to
be avoided, is based on secondary post-hoc analyses
conducted on a limited number of studies, none of
them originally designed to evaluate mortality as the
primary end-point. Thus, the findings of this meta-analysis
have to be considered as hypothesis-generating rather than
hypothesis-testing. Apart from this, the associations
derived from meta-regressions are observational in nature,
and have a weaker interpretation than the causal relation-
ships derived from randomized comparisons.
In conclusion, we agree with Gueyffier et al. on being
cautious and not lower the BP too much in a frail elderly
patient, and, as we stated, physicians should pursue ‘wise’
rather than ‘arbitrary’ targets, tailor therapy to the indi-
vidual patient, and carefully balance between clinically
significant benefits and possible, yet unproven, harmful
effects.
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